---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Generic, brand name and therapeutic class of product. Topics: Manufacturer: ORIC Pharmaceuticals, Proposed international nonproprietary name, Recommended international nonproprietary name, Former company code ORIC-944, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: ORIC Pharmaceuticals

> “ORIC will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor, NUBEQA ® (darolutamide), at no cost for use in the trial in combination with rinzimetostat.”
> “This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.1.2.1-2"></a>

### Proposed international nonproprietary name

> “rinzimetostatum”
> “2369769-29-7”

Source: [WHO Drug Information Proposed INN List 133 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf)

<a id="topic-2.1.2.1-3"></a>

### Recommended international nonproprietary name

> “Recommended INN: List 95”
> “rinzimetostatum”

Source: [WHO Drug Information Recommended INN List 95 (2026)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl95.pdf)

<a id="topic-2.1.2.1-4"></a>

### Former company code ORIC-944

> “Rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.1-5"></a>

### Synonyms and originator code MRTX2219

> “MRTX2219”
> “ORIC-944”
> “9X4NP88TGB”

Source: [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full)

<a id="topic-2.1.2.1-6"></a>

### Therapeutic class

> “rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.1.2.1-7"></a>

### Brand name

No evidence found.

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
